Haruyasu Murakami

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

Alexander Drilon, Salvatore Siena, Rafał Dziadziuszko et al. · The Lancet Oncology · 2019 · 516 citations · Full text

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

Kiyotaka Yoh, Takashi Seto, Miyako Satouchi et al. · The Lancet Respiratory Medicine · 2016 · 292 citations

Non-small-cell Lung Cancer, Multicentre Phase 2, Medicine +7

The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer

Hirotsugu Kenmotsu, Tateaki Naito, Madoka Kimura et al. · Journal of Thoracic Oncology · 2011 · 226 citations · Full text

Inflammatory Lung Disease, Advanced Lung Disease, Lung Inflammation +9

Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial

Jun Sato, Miyako Satouchi, Shoichi Itoh et al. · The Lancet Oncology · 2020 · 203 citations

Oncology, Metastatic Thymic Carcinoma, Metronomic Therapy +5

Increases of Amphiregulin and Transforming Growth Factor-α in Serum as Predictors of Poor Response to Gefitinib among Patients with Advanced Non–Small Cell Lung Cancers

Nobuhisa Ishikawa, Yataro Daigo, Atsushi Takano et al. · Cancer Research · 2005 · 191 citations